The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients.

The latest move follows a priority review of a supplemental new drug application (sNDA) for the therapy.

In 2017, the therapy received FDA approval for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.

The drug is given once a day as an oral tablet or as an injection for intravenous infusion.

Merck Research Laboratories global clinical development vice-president Dr Elizabeth Rhee stated: “PREVYMIS has been an important addition to the care of high-risk adult CMV-seropositive patients who have received allogeneic stem cell transplants to help prevent CMV infection and disease.

“We are delighted that PREVYMIS is now approved to help prevent CMV disease in adult kidney transplant patients at high risk.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“At Merck, we are proud to continue to bring innovative medicines to people to address serious infectious diseases.”

The regulatory approval was supported by a double-blind, randomised, multicentre, active comparator-controlled non-inferiority Phase III trial conducted in 589 adult kidney transplant recipients at high risk of CMV.

The trial’s main objective was to assess the efficacy of letermovir against valganciclovir (VGCV).

PREVYMIS was found to be superior to valganciclovir in terms of the primary endpoint of incidence of CMV disease through to week 52 following kidney transplantation.